IC-OS Weekly Webinar - Managing Bleeding Risk with BTK inhibitors in Cardio-Oncology patients

Craig Beavers, Pharm.D., graduated in 2009 from the University of Kentucky (UK) College of Pharmacy and completed a Postgraduate Year One Pharmacy Practice residency and a Postgraduate Year Two Cardiology Pharmacy residency at UK Albert B. Chandler Hospital in Lexington, Kentucky. Beavers is the current Director of Cardiovascular Services at Baptist Health Paducah. Beavers recently served as the cardiovascular clinical pharmacy coordinator at UK Healthcare and with the UK Gill Heart Institute, as the Director of Cardiovascular Services for the Hospital Corporation of America, and a cardiovascular clinical pharmacy specialist with TriStar Centennial Medical Center. Previously he was adjunct faculty for Lipscomb University College of Pharmacy, University of Tennessee College of Pharmacy, and served as the Postgraduate Year Two Cardiology Pharmacy Residency Program Director at TriStar Centennial Medical Center in Nashville, Tennessee. Beavers currently is an assistant adjunct professor with the University of Kentucky College of Pharmacy. Beavers currently serves as the chair of the American College of Cardiology’s (ACC) Cardiovascular Team Council and was the previous co-chair of the ACC’s Clinical Pharmacist Workgroup. He is the first pharmacist to be a Cardiovascular Professional for the Society for Cardiovascular Angiography and Interventions (SCAI) and serves on SCAIs Quality Committee. In addition, he is an active member of the American Heart Association, American Society of Health-System Pharmacist, American Pharmacist Association, Kentucky Society of Health-System Pharmacist. He has published numerous papers, abstracts, and textbook chapters and presented internationally on topics focused on cardiovascular pharmacotherapy and cardiovascular quality improvement. He is Board Certified in Pharmacotherapy with Added Qualifications in Cardiology and a Board Certified Cardiology Pharmacist from the Board of Pharmacy Specialties. Beavers is also a Board Certified Anticoagulation Care Provider. He is a fellow of the American Heart Association and Fellow of the American College of Cardiology.

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

Sarah is a Board-Certified Oncology Pharmacist at North Memorial Health Care in Minneapolis, MN. She is passionate about patient-directed cancer care and late-breaking research in clinical pharmacy, inpatient supportive care, and Hematology/Oncology practice. She completed her PGY-2 Hematology/Oncology Residency at the University of Minnesota Medical Center and serves as a lecturer at the University of Minnesota College of Pharmacy.